Trial Profile
A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 and GW642444 as Monotherapies and Concurrently in Healthy Japanese Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary) ; Vilanterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GSK
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
- 02 Feb 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from recruiting to completedas reported by ClinicalTrials.gov.